Rosadas, Carolina, Khan, Maryam, Parker, Eleanor, Marchesin, Federica, Katsanovskaja, Ksenia, Sureda-Vives, Macia, Fernandez, Natalia, Randell, Paul, Harvey, Ruth, Lilley, Alice et al (show 28 more authors)
(2022)
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.
JOURNAL OF VIROLOGICAL METHODS, 302.
114475-.
Abstract
Accurate and sensitive detection of antibody to SARS-CoV-2 remains an essential component of the pandemic response. Measuring antibody that predicts neutralising activity and the vaccine response is an absolute requirement for laboratory-based confirmatory and reference activity. The viral receptor binding domain (RBD) constitutes the prime target antigen for neutralising antibody. A double antigen binding assay (DABA), providing the most sensitive format has been exploited in a novel hybrid manner employing a solid-phase S1 preferentially presenting RBD, coupled with a labelled RBD conjugate, used in a two-step sequential assay for detection and measurement of antibody to RBD (anti-RBD). This class and species neutral assay showed a specificity of 100 % on 825 pre COVID-19 samples and a potential sensitivity of 99.6 % on 276 recovery samples, predicting quantitatively the presence of neutralising antibody determined by pseudo-type neutralization and by plaque reduction. Anti-RBD is also measurable in ferrets immunised with ChadOx1 nCoV-19 vaccine and in humans immunised with both AstraZeneca and Pfizer vaccines. This assay detects anti-RBD at presentation with illness, demonstrates its elevation with disease severity, its sequel to asymptomatic infection and its persistence after the loss of antibody to the nucleoprotein (anti-NP). It also provides serological confirmation of prior infection and offers a secure measure for seroprevalence and studies of vaccine immunisation in human and animal populations. The hybrid DABA also displays the attributes necessary for the detection and quantification of anti-RBD to be used in clinical practice. An absence of detectable anti-RBD by this assay predicates the need for passive immune prophylaxis in at-risk patients.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Sars-CoV-2, ELISA, Receptor binding domain, Antibodies |
Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences |
Depositing User: | Symplectic Admin |
Date Deposited: | 28 Feb 2022 08:48 |
Last Modified: | 18 Jan 2023 21:11 |
DOI: | 10.1016/j.jviromet.2022.114475 |
Open Access URL: | https://doi.org/10.1016/j.jviromet.2022.114475 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3149798 |